Table 1.
Demographic, biochemistry, and sleep data of all the 88 study participants in the validation cohort
| PS subjects (n = 24) | Severe OSA patients (n = 64) | p value | |
|---|---|---|---|
| Age, years | 45.6 ± 10.7 | 47 ± 11.1 | 0.595 |
| Male sex, n (%) | 17 (70.8) | 53 (82.8) | 0.215 |
| BMI, kg/m2 | 25 ± 3.5 | 25.8 ± 2.7 | 0.259 |
| AHI, events/hour | 4.2 ± 3 | 47.1. ± 19.4 | < 0.001 |
| ODI, events/hour | 1.1 ± 0.9 | 33.0 ± 23.5 | < 0.001 |
| Mean SpO2, % | 94.8 ± 1.5 | 92.5 ± 12.7 | 0.606 |
| Minimum SpO2, % | 90.0 ± 2.2 | 75.5 ± 17.6 | 0.024 |
| Snoring index, counts/hour | 139 ± 126 | 390 ± 214 | 0.008 |
| Arousal index, events/hour | 21.9 ± 18.1 | 48.7 ± 30.9 | 0.014 |
| Epworth sleepiness scale | 5.5 ± 4.1 | 9.5 ± 4.2 | 0.032 |
| Excessive daytime sleepiness, n (%) | 4 (16.7) | 25 (39.1) | 0.089 |
| MCFSI | 1.917 ± 2.376 | 3.305 ± 2.571 | 0.024 |
| Cognitive dysfunction, n (%) | 4 (16.7) | 17 (26.6) | 0.332 |
| Daytime fatigue, n (%) | 8 (33.3) | 44 (68.8) | 0.007 |
| Memory impairment, n (%) | 12 (50) | 40 (42.5) | 0.546 |
| Morning headache, n (%) | 4 (16.7) | 14 (21.9) | 0.759 |
| Nocturia, n (%) | 7 (29.2) | 37 (57.8) | 0.044 |
| Smoking history, n (%) | 10 (41.7) | 21 (32.9) | 0.625 |
| Alcoholism history, n (%) | 0 (0) | 1 (1.6) | 0.538 |
| Cholesterol, mg/dl | 192.4 ± 31.2 | 195.5 ± 37.9 | 0.95 |
| Triglycerides, mg/dl | 129.1 ± 80.5 | 149.1 ± 132.3 | 0.497 |
| Co-morbidities | |||
| Hypertension, n (%) | 6 (25) | 21 (32.8) | 0.479 |
| Diabetes mellitus, n (%) | 3 (12.5) | 4 (6.3) | 0.335 |
| Heart disease, n (%) | 1 (4.2) | 5 (7.8) | 0.546 |
| Stroke, n (%) | 0 (0) | 2 (3.1) | 0.381 |
| CKD, n (%) | 1 (4.2) | 1 (1.6) | 0.465 |
| Depression, n (%) | 2 (8.3) | 16 (25) | 0.125 |
PS Primary snoring; HS Healthy subjects; BMI Body mass index; AHI Apnea hypopnea index; ODI Oxygen desaturation index; SpO2 Pulse oxyhemoglobin saturation; ESS Epworth Sleepiness Scale; EDS Excessive daytime sleepiness; MCFSI Mail-in cognitive function screening instrument; CKD Chronic kidney disease